Investor Presentaiton

Sartorius Group M&A strategy - adding innovation, enhancing focus Essen BioScience Life Science assets from Danaher 2017 2019 2020 Umetrics Biological Industries Acquisition criteria 10 10 ALS 2021 2022 2023 xell BIA Separations WaterSep CellGenix Xell Chrom. assets from Novasep Albumedix Portfolio: Complementary products or technologies Market position: Either among the Top 3 or unique selling point Integration: Management capacity; cultural fit Price: Fair valuation; reach Sartorius' profitability level in 2-3 years Polyplus Polyplus SARTORIUS

View entire presentation